The results, announced this week by Moderna and Merck, could pave the way for a new generation of treatments tailored to ...
Vivian Campbell has been battling Hodgkin’s lymphoma since 2013, but there was hope last year that his fight would be over.
Intismeran autogene is a personalized mRNA therapy that targets a tumor's unique mutational signature to trigger an anticancer immune response.
Pharmaceutical companies have shown little interest in dialing back recommended dosages. Once they set the price for a drug, the more sales, the more profit. One study that examined 29 expensive ...
Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...
Moderna and Merck's personalised cancer vaccine succeeds in a Phase 3 trial, raising hopes for a new generation of cancer ...
FDA fast track status supports accelerated development of PLN-101095 plus pembrolizumab for ICI-refractory solid tumors, ...
A lower dose might work as well or help avoid side effects. But few people in the U.S. healthcare system — beyond patients — ...
US drugmakers Merck and Moderna said Wednesday an experimental melanoma drug that delivers treatment tailored to a patient's specific tumor prevented the cancer from returning in a large clinical ...
The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells ...
A personalized mRNA vaccine for melanoma reduced the risk of the cancer returning in a phase III clinical trial, the ...
Researchers, doctors and patients are pushing for extra studies to help find the right dosage for an array of cancer drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results